The Latest: On January 31 2024, Biogen announced it will be discontinuing Alzheimer’s disease drug Aduhelm (aducanumab-avwa) by returning it to Neurimmune, its original owner, for a one-time charge of USD60mn. Biogen licensed Aduhelm from Neurimmune in 2007 under a collaborative development and license agreement. Aduhelm received FDA accelerated

The Latest: On January 24 2024, the Swedish Buy Now, Pay Later (BNPL) company Klarna, announced that it was launching a subscription service called Klarna Plus in the US. This service, available through the Klarna app for a monthly fee of USD7.99 and offers members special benefits such as no service fees on Klarna's One Time Card, double rewards

Key View

• We continue to forecast that US real GDP growth will slow to 1.4% in 2024, from 2.5% in 2023. The economy grew by a strong 3.3% on a q-o-q annualised basis in Q423, following a blockbuster 4.9% print in Q323.
• As we outlined in early January, we expect that growth will ease but remain close to trend in Q124 given looser financial

Key View

• John Deere's partnership with SpaceX will enhance rural connectivity for farmers by integrating Starlink satellite broadband into their precision agriculture equipment with the aim of improving productivity and sustainability.
• The partnership will offer a competitive edge to poorly serviced agribusinesses in rural areas which could

The Latest: On January 14 2024, Lupin announced that it had received US FDA approval to market a generic version of propranolol hydrochloride extended-release capsules, used in the treatment of migraine and hypertension. The approval is significant as Lupin can offer a more affordable alternative to ANI Pharmaceuticals' Inderal LA extended

Key View

• GE HealthCare’s agreement to acquire MIM Software will support the company’s digital transformation strategy. 
• Mergers and acquisitions will become a key feature of GE HealthCare’s digital transformation strategy as the company aims to expand its digital capabilities and precision care offerings.
• Radiology will continue to dominate

Key View

• Florida’s plan to import drugs from Canada will face many obstacles despite FDA approval.
• The Pharmaceutical Research and Manufacturers of America industry group is likely to launch legal action against the program, which will benefit drugmakers.
• However, ongoing drug shortages and high pharmaceutical costs will persist in the US

The Latest: On January 9 2024, Venatorx and Menarini announced that they had entered into an agreement for the commercialisation of Venatorx’s investigational drug, cefepime-taniborbactam, an antibiotic being developed for the treatment of complicated urinary tract infections (cUTIs). Under the terms of the agreement, Menarini has obtained

Key View

• Growth in the US medical devices market will slow in 2024, reflecting a challenging macroeconomic environment.
• New regulation and legislation on artificial intelligence (AI)-enabled medical devices in the US will reduce short-term product approvals but provide long-term benefits to the medical devices market.
• Strengthening medical

The Latest: On December 21 2023, a letter sent to House Budget Committee Chair Jodey Arrington (R-TX) and Michael Burgess (R-TX) reported that the Congressional Budget Office (CBO) anticipates pharmaceutical companies will increase list prices for new drugs while simultaneously offering larger rebates in response to policies found within the